A randomized trial assessing the immunogenicity and reactogenicity of two hexavalent infant vaccines concomitantly administered with group b meningococcal vaccine by Rajan, M, Marchevsky, N, Sinclair, G, O'Brien, K, Jefferies, K, Owino, N, Hallis, B, Goldblatt, D, Matheson, M, Cuthbertson, H, Aley, P, Snape, MD, Liu, X

Transmission of SARS-CoV-2 in the household setting: a prospective cohort study in children and adults in England by Miller, E, Waight, PA, Andrews, NJ, McOwat, K, Brown, KE, Katja, H, Ijaz, S, Letley, L, Haskins, D, Sinnathamby, M, Cuthbertson, H, Hallis, B, Parimalanathan, V, de Lusignan, S, Lopez-Bernal, J

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised co... by Davis, K, Valente Pinto, M, Andrews, NJ, Goldblatt, D, Borrow, R, Findlow, H, Southern, J, Partington, J, Plested, E, Patel, S, Holland, A, Matheson, M, England, A, Hallis, B, Miller, E, Snape, M

Influenza A virus challenge models in Cynomolgus macaques using the authentic inhaled aerosol and intra-nasal routes of infection by Marriott, A, Dennis, M, Kane, J, Gooch, K, Hatch, G, Sharpe, S, Prevosto, C, Leeming, G, Zekeng, E, Staples, K, Hall, G, Ryan, K, Bate, S, Moyo, N, Whittaker, C, Hallis, B, Silman, N, Lalvani, A, Wilkinson, T, Hiscox, J, Stewart, J, Carroll, M

Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective cohort study and analysis of transcriptomic predictors of response by Drennan, PG, Provine, NM, Harris, SA, Otter, A, Hollett, J, Cooper, C, De Maeyer, RPH, Nassanga, B, Ateere, A, Pudjohartono, MF, Peng, Y, Chen, J-L, Jones, S, Fadzillah, NHM, Grifoni, A, Sette, A, Satti, I, Murray, SM, Rowe, C, Mandal, S, Hallis, B, Klenerman, P, Dong, T, Richards, D, Fullerton, J, McShane, H, Coles, M

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial by Folegatti, PM, Ewer, KJ, Aley, PK, Angus, B, Becker, S, Belij-Rammerstorfer, S, Bellamy, D, Bibi, S, Bittaye, M, Clutterbuck, EA, Dold, C, Faust, SN, Finn, A, Flaxman, AL, Hallis, B, Heath, P, Jenkin, D, Lazarus, R, Makinson, R, Minassian, AM, Pollock, KM, Ramasamy, M, Robinson, H, Snape, M, Tarrant, R, Voysey, M, Green, C, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ, Oxford COVID Vaccine Trial Group

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials by Voysey, M, Flaxman, A, Aboagye, J, Aley, PK, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Charlton, S, Clutterbuck, EA, Davies, S, Dold, C, Edwards, NJ, Ewer, K, Faust, SN, Folegatti, PM, Fowler, J, Gilbride, C, Gilbert, SC, Godfrey, L, Hallis, B, Humphries, HE, Jenkin, D, Kerridge, S, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Snape, MD, Song, R, Thomas, KM, Ulaszewska, M, Woods, D, Wright, D, Pollard, AJ, Lambe, T

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-i... by Liu, X, Shaw, RH, Stuart, ASV, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Dinesh, T, England, A, Faust, SN, Ferreira, DM, Finn, A, Green, CA, Hallis, B, Heath, PT, Hill, H, Lambe, T, Lazarus, R, Libri, V, Long, F, Mujadidi, YF, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Singh, N, Turner, DPJ, Turner, PJ, Walker, LL, White, R, Nguyen-Van-Tam, JS, Snape, MD

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV,... by Shaw, RH, Liu, X, Stuart, ASV, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Dejnirattisai, W, Dinesh, T, Faust, SN, Ferreira, DM, Finn, A, Green, CA, Hallis, B, Heath, PT, Hill, H, Lambe, T, Lazarus, R, Libri, V, Long, F, Mujadidi, YF, Plested, EL, Morey, ER, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, Walker, LL, White, R, Nguyen-Van-Tam, JS, Snape, MD

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adj... by Shaw, RH, Greenland, M, Stuart, AS, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJ, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Lambe, T, Libri, V, Lillie, PJ, Morey, E, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Mary Ramsay, F, Read, RC, Hannah Robinson, RN, Screaton, GR, Singh, N, Turner, DP, Turner, PJ, Rachel White, RN, Nguyen-Van-Tam, JS, Liu, X, Snape, MD

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera by Zhou, D, Dejnirattisai, W, Supasa, P, Liu, C, Mentzer, AJ, Ginn, HM, Zhao, Y, Duyvesteyn, HME, Tuekprakhon, A, Nutalai, R, Wang, B, Paesen, GC, Lopez-Camacho, C, Slon-Campos, J, Hallis, B, Coombes, N, Bewley, K, Charlton, S, Walter, TS, Skelly, D, Lumley, SF, Dold, C, Levin, R, Pollard, AJ, Dong, T, Knight, JC, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, S, James, W, Carroll, MW, Klenerman, P, Barnes, E, Dunachie, SJ, Fry, EE, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a sing... by Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses by Barrett, J, Belij-Rammerstorfer, S, Dold, C, Ewer, KJ, Folegatti, PM, Gilbride, C, Halkerston, R, Hill, J, Jenkin, D, Stockdale, L, Verheul, MK, Aley, PK, Angus, B, Bellamy, D, Berrie, E, Bibi, S, Bittaye, M, Carroll, MW, Cavell, B, Clutterbuck, EA, Edwards, N, Flaxman, A, Fuskova, M, Gorringe, A, Hallis, B, Kerridge, S, Lawrie, AM, Linder, A, Liu, X, Madhavan, M, Makinson, R, Mellors, J, Minassian, A, Moore, M, Mujadidi, Y, Plested, E, Poulton, I, Ramasamy, MN, Robinson, H, Rollier, CS, Song, R, Snape, MD, Tarrant, R, Taylor, S, Thomas, KM, Voysey, M, Watson, MEE, Wright, D, Douglas, AD, Green, CM, Hill, AVS, Lambe, T, Pollard, AJ

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial by Ramasamy, MN, Minassian, AM, Ewer, KJ, Flaxman, AL, Folegatti, PM, Owens, DR, Voysey, M, Aley, PK, Angus, B, Babbage, G, Belij-Rammerstorfer, S, Berry, L, Bibi, S, Bittaye, M, Cathie, K, Chappell, H, Charlton, S, Cicconi, P, Clutterbuck, EA, Colin-Jones, R, Dold, C, Emary, KRW, Fedosyuk, S, Fuskova, M, Gbesemete, D, Green, C, Hallis, B, Hou, MM, Jenkin, D, Joe, CCD, Kelly, EJ, Kerridge, S, Lawrie, AM, Lelliott, A, Lwin, MN, Makinson, R, Marchevsky, NG, Mujadidi, Y, Munro, APS, Pacurar, M, Plested, E, Rand, J, Rawlinson, T, Rhead, S, Robinson, H, Ritchie, AJ, Ross-Russell, AL, Saich, S, Singh, N, Pollard, AJ, Oxford COVID Vaccine Trial Group

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera by Supasa, P, Zhou, D, Dejnirattisai, W, Liu, C, Mentzer, AJ, Ginn, HM, Zhao, Y, Duyvesteyn, HME, Nutalai, R, Tuekprakhon, A, Wang, B, Paesen, GC, Slon-Campos, J, López-Camacho, C, Hallis, B, Coombes, N, Bewley, KR, Charlton, S, Walter, TS, Barnes, E, Dunachie, SJ, Skelly, D, Lumley, SF, Baker, N, Shaik, I, Humphries, HE, Godwin, K, Gent, N, Sienkiewicz, A, Dold, C, Levin, R, Pollard, AJ, Dong, T, Screaton, GR, Knight, JC, Klenerman, P, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, S, Hall, DR, Williams, MA, Paterson, NG, James, W, Carroll, MW, Fry, EE, Mongkolsapaya, J, Stuart, DI

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the C... by Liu, X, Munro, APS, Feng, S, Janani, L, Aley, PK, Babbage, G, Baxter, D, Bula, M, Cathie, K, Chatterjee, K, Dejnirattisai, W, Dodd, K, Enever, Y, Qureshi, E, Goodman, AL, Green, CA, Harndahl, L, Haughney, J, Hicks, A, van der Klaauw, AA, Kwok, J, Libri, V, Llewelyn, MJ, McGregor, AC, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Serafimova, T, Saralaya, D, Screaton, GR, Sharma, S, Sheridan, R, Sturdy, A, Supasa, P, Thomson, EC, Todd, S, Twelves, C, Read, RC, Charlton, S, Hallis, B, Ramsay, M, Andrews, N, Lambe, T, Nguyen-Van-Tam, JS, Cornelius, V, Snape, MD, Faust, SN